Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Theranos
Theranos, the embattled blood-testing company, said on Monday it has reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve its regulatory issues.
The terms: CMS has reversed its revocation of Theranos's CLIA operating license, though the company maintains that it won't operate or own a lab for at least the next two years, which is in line with its recent business shift to building a device to sell to clinics. Theranos will pay $30,000 to settle its fines.
Why it matters: Following a series of reports by the Wall Street Journal starting in October 2015 that raised questions about the company's technology, Theranos has faced scrutiny from regulators, lost business partners, voided some of its test results, and shut down its clinics in an attempt to retool its business model.